Hi everyone!  I'm happy to have found this forum while doing a  google search for natural remedies.  I was diagnosed around 1983 (about 10 years old) with a generic "psoriasis" diagnosis.  In the beginning it covered both of my legs.  I don't recall at the time if they gave me any treatment?  That was thirty some odd years ago....

In my twenties it emerged again on my scalp, a spot here and there on my arms, elbows, back, stomach.  Using various natural and over-the-counter lotions, creams, and sunlight/tanning beds have kept it pretty under control and felt very fortunate.

Two years ago, during an extremely stressful period of my life, it explodes on my scalp and I lost all of my hair. Well, half of my hair and then I cut the rest off because I was tired of handfuls coming out in the shower every day.  I'm happy to say my hair has grown back fuller and thicker than ever and my scalp has calmed down.  Currently, I use shea moisture coconut oil on my hair about every other day, massaging through hair and scalp and leave it on overnight.  Coconut oil has seemed to provide the best relief for my scalp.

But a year ago the rest of my skin went nuts with P.  Arms, elbows, torso, legs, back.  At that time, I'm guessing it was covering about 60% of my body.  I've been using a combination of prescribed steroid cream (Mometasone), coconut oil, UVB tanning bed 2-3x a week, CeraVe Psoriasis Cream, and now adding baking soda baths.  My family doctor prescribes the Mometasone and asked me if I wanted to be referred to a dermatologist however I don't have any health insurance right now.  I'm interested in natural/cost friendly treatments.

I've had many flares and remissions over my life.  It doesn't seem to be triggered by anything consistently other than stressful times.  Hangs around a year or a couple and then fades away again.  The baking soda baths have given me much relief from the itching, redness, scaling.  This flare has been going on exactly a year so far, but it is getting better and gradually clearing.  I would estimate it's down to about 30% of my body.

I've found so much great information here already, and it's a comfort to know there are people out there who understand.   

Glad to be here, this seems like a great group!
Lillie

Could images help in psoriasis diagnosis in parts of China ?

Quote:

---

Background:
Psoriasis is a chronic inflammatory skin disease which holds a high incidence in China. However, professional dermatologists who can diagnose psoriasis early and correctly are insufficient in China, especially in the rural areas. A smart approach to identify psoriasis by pictures would be highly adaptable countrywide, and could play a useful role in early diagnosis and regular treatment of psoriasis.

Objectives:
Design and evaluation of a smart psoriasis identification system based on clinical images (without relying on a dermatoscope) that works effectively similar to a dermatologist.

Methods:
A set of deep learning models using convolutional neural networks (CNNs) were explored and compared in the system for automatic identification of psoriasis. The work was carried out on a standardized dermatological dataset with 8021 clinical images of 9 common disorders including psoriasis along with full electronic medical records of patients built over the last 9 years in China. A two‐stage deep neural network was designed and developed to identify psoriasis. In the first stage, a multi‐label classifier was trained to learn the visual patterns for each individual skin disease. In the second stage, the output of the first stage were utilized to distinguish psoriasis from other skin diseases.

Results:
The area under the curve (AUC) of the two‐stage model reached 0.981±0.015, which outperforms a single‐stage model. And the classifier showed superior performance (missed diagnosis rate: 0.04, misdiagnosis rate: 0.03) than 25 Chinese dermatologists (missed diagnosis rate: 0.09, misdiagnosis rate: 0.27) in the diagnosis of psoriasis on 100 clinical images.

Conclusions:
Using clinical images to identify psoriasis is feasible and effective based on CNNs, which also builds a solid technical base for smart care of skin diseases especially psoriasis using mobile/tablet applications for teledermatology in China.

hi all, I’m new to the forum.  I started taking Skilerence three weeks ago and Ive worked my way up to 120 mg per day so far.  Side effects are ok at the moment. A bit of skin irritation but only lasts 10-20mins so bearable.  The only thing is that my skin looks worse! Is this something that can happen? Does it look worse before it gets better or does it take a while to kick in if it works? Confused.

Skilerance is a great drug and works but the side affects for me on 120 mg is not bearable.
I've tried it with food and yogurt, I've even cut the tablet in half and hid it in a soft sweet and swallowed half in the morning and half late afternoon but the cramps i get and sweats and going red is crazy.
I need to inform my dermatologist but after being on methotrexate and cyclosporine, I don't now what other options I have.
Any suggestions would be welcome as i'm sure you all know how i'm feeling. 

Hi.. Ive been search this place and also the inspire page in the US and although GI / diarrhea is a listed side effect there doesnt seem much else on it: Novartis is stating it cannot cause IBD... it can only bring it on if the person had it already but I have seen one person on this page and another in the US who did not have it before, and do have it now. 
I think I fall into this category... the pain started on my second monthly dose after the 5 loading doses...I was doing really well until then and the GI issues were severe: severe diarrhea for a week with severe cramping.. this lasted a month, now I am on anti ulcer meds which help a little with pain but the pain was across the whole system from stomach down to colon. though mostly upper. 
Am waiting for tubes and cameras but the wait list is a while! ... has anyone else experienced this? They are suggestingI change to a different biologic but I am quite worried about trying something new now.... I basically lost a month of my life lying in bed or running to the loo!

Hi!

Found this site while browsing for information on biologics.  I have been diagnosed with plaque psoriasis , which is hereditary in my family, 25 years ago and psoriatic arthritis  (the first in the family) 10 years ago.  Wow, writting this down  makes me feel old!

Started on biologics 2 years ago because of the arthritis.   I was tired of being in pain. Still am!

I am on Cosentyx which pretty much cleared up my psoriasis   but my rheumatologist just increased the dose as it wasn't doing anything for the arthritis.  Hope it works!

Tried humira and stelara before.

Thanks for letting me join!
Kat

Figures vary on how many people with psoriasis will go on to get psoriatic arthritis but it is around 1/4.

Psoriatic arthritis (PsA)
• When joints are inflamed they become tender, swollen and painful on movement.
• Joints are typically stiff after resting, early morning or resting in the evening.
• Tissues such as ligaments, tendons around the joints may be involved.
• Inflammation of tendon or muscle (such as tennis elbow (Lateral Epicondylitis) and pain around the heel) is also a feature in those with psoriatic arthropathy.
• In approximately 80% of cases the arthritis develops after the appearance of psoriasis.
• In 20% of cases the joint inflammation comes first.

Joints normally function to allow movement to occur between bone ends, which are important for the body to move. Bone ends are covered with cartilage around which is a capsule lined by a membrane called synovium.
This membrane normally makes the fluid that lubricates the joint space allowing movement. In arthritis the synovial membrane becomes inflamed - and releases substances that cause inflammation.
The inflamed synovium releases more fluid than normal and so the joint becomes tender and swollen. Persistent inflammation may lead to damage to the cartilage and erosion of the underlying bone.
Synovial membrane also lines and lubricates tendons and so they become inflamed too.

There are several features that distinguish (PsA) from other forms of arthritis:
• Particular patterns of joints that may be involved.
• One pattern of inflammation is usually in the end joints of fingers often corresponding with the fingers that have psoriatic nail involvement, which is more common in men than women.
• Another pattern is involvement of the joints of the spine and sacroiliac joints which is called spondylitis similar to ankylosing spondylitis.
• Neck pain and stiffness.
• An entire toe or finger can become swollen or inflamed which is termed dactylitis.
• There is a tendency for joints to stiffen up and sometimes to fuse together.
• Importantly the absence of rheumatoid factor in the blood helps distinguish psoriatic arthritis from rheumatoid arthritis.
• Distinguishing features are not always present and the individual may have swelling of a few or many joints that is similar to other types of arthritis making diagnosis difficult.

In 80% of individuals with arthritis, psoriatic nail changes are found, which is more common than with psoriasis alone.
Nail changes include pitting, discolouration of the nail due to abnormalities in the growth of tissue in the nailbed.
The risk of developing arthritis is greater in individuals with severe psoriasis, yet occasionally severe arthritis may occur with minimal skin disease.

Howdy - Currently on Cosentyx for 4 mo, generally feeling better yay! 

But having sudden sharp mental decline. Can still recite and analyze passages from Chaucer and Shakespeare no prob (retired Engl Lit teacher) but cant remember to lock the front door when I go out, turn off the coffee pot, pay bills on time, and recently had a “spell” where I was driving to a dr’s appmnt, got confused, then lost, and ended up driving all over town for an afternoon - didnt know where I was going, or why, or where I was, or how to get home. I have lived in this same small town for 20 years! 

Has anyone else experienced mental confusion while on Cosentyx? It is not listed as a side effect. Or could this be something else? 

TIA,

I’m not really a cowboy, it’s just an avatar. I’m really a middle aged urban Texan (having lived in NYC, LA, Wash DC, San Fran, as well as Houston and various DFW ‘burbs.), although I have Tx cred via various relatives. Diagnosed w psoriasis as a teen, and PsA at midlife. It ebbs and flows, and I am not entirely certain any of my meds are doing much to control it. So glad I found this forum, bc I don’t know anyone else who has it, that I can talk to, who understands.

This study evaluates the efficacy and safety of recommended Taltz (ixekizumab) dose over 4 years.

Quote:

---

Background:
Psoriasis, a chronic disease usually requires long‐term disease management.

Objective:
This study evaluates the efficacy and safety of recommended ixekizumab (IXE) dose over 4 years (204 weeks) from UNCOVER‐3 study.

Methods:
UNCOVER‐3 was a randomized, double‐blind, multicenter, Phase 3 study wherein patients with moderate‐to‐severe plaque psoriasis received placebo, IXE 80 mg every 2 weeks (Q2W), IXE 80 mg every 4 weeks (Q4W) (both IXE groups had 160 mg starting dose), or etanercept 50 mg twice weekly. At Week 12, all patients switched to IXE Q4W dose for the long‐term extension (264 weeks). After Week 60 and at investigator's discretion, patients could receive dose adjustment to IXE Q2W. The efficacy endpoints at Week 204 were percentage of patients achieving PASI 75/90/100, sPGA score of 1 or 0, and those achieving PSSI=0, NAPSI=0, and PPASI 100. Efficacy data were summarized through 204 weeks using as‐observed, multiple imputation (MI), and modified nonresponder imputation (mNRI) methods.

Results:
The proportion of patients achieving PASI 75/90/100 at Week 204 using mNRI method were 82.8%, 66.4%, and 48.3%, respectively. Using as‐observed and MI methods, 98.2% and 94.8% patients achieved PASI 75, 87.8% and 73.3% achieved PASI 90, and 67.1% and 52.7% achieved PASI 100 response, respectively, at Week 204. The response rates for sPGA (0, 1) were 88.7%, 76.2%, 68.5% and for sPGA (0) were 68.9%, 54.6%, and 49.7% using as‐observed, MI, and mNRI methods, respectively. Similar trends were observed with NAPSI=0, PSSI=0, PPASI 100, and itch NRS=0. There were no new safety concerns through Year 4.

Conclusions:
This study demonstrated sustained high‐efficacy response through 4 years of continuous treatment with ixekizumab in patients with moderate‐to‐severe plaque psoriasis. The safety profile remained consistent with prior findings, with no new or unexpected safety concerns.

Looks like another drug failed due to diarrhoea.
 I tried Oteza. It was working but the longer I was on it, the worse my diarrhoea got.
I am now on Skilerence. Only got to 2x 120mg tablets a day. No will I get to 6 a day. Horrendous stomach pains at times, but the diarrhoea is now bad

Very limited what I can take due to high blood pressure

This study looked at quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF)

Quote:

---

Background:
Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment. BRIDGE was a randomised, double‐blind, phase III study comparing the efficacy and safety of dimethylfumarate (DMF) with a fixed combination of fumaric acid esters (FAE) or placebo for the treatment of moderate‐to‐severe psoriasis.

Objectives:
This post‐hoc analysis investigated treatment effect on QoL overall and by patient sub‐groups categorised by disease severity. Week 8 efficacy responses were also investigated as possible predictors of Week 16 Dermatology Life Quality Index (DLQI) outcomes.

Methods:
Patients were randomised to receive a maximum daily dose of 720 mg of DMF, FAE (gradual up‐titration) or placebo for 16 weeks. Psoriasis Area Severity Index, Body Surface Area, Physician's Global Assessment and DLQI were assessed at baseline, Week 8 and 16. DLQI 0–1 indicated ‘no effect on patient life’. Associations between baseline severity,

Week 16 DLQI and Week 8 efficacy (as observed cases) were also examined.

Results:

At baseline, 671 patients were included in the full analysis set (267 randomised to DMF, 273 to FAE and 131 to placebo). DMF was superior to placebo (P < 0.001) and not significantly different to FAE regarding Week 16 DLQI outcomes (P > 0.05). Baseline disease severity did not impact DLQI outcomes at Week 16. In DMF‐ and FAE‐treated patients, Week 8 PASI 50/75 responders reported better DLQI responses at Week 16 vs non‐responders (P < 0.05). Week 8 PASI ≤3 and/or PGA 0–1 responders were also more likely to report DLQI 0–1 at Week 16 vs non‐responders (P < 0.05).

Conclusion:
DMF significantly improved DLQI outcomes versus placebo and was not affected by baseline disease severity. Efficacy responses (PASI 50/75, PASI ≤3 and PGA 0–1) as early as Week 8 were predictive of QoL outcomes at Week 16 in DMF‐ and FAE‐treated patients.

Following on from Skyrizi gets positive opinion from CHMP Skyrizi (risankizumab) has been given the go ahead from NICE (National Institute for Health and Care Excellence) in the treatment of moderate to severe plaque psoriasis.

Quote:

---

Risankizumab is recommended as an option for treating plaque psoriasis in adults, only if: The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and the company provides the drug according to the commercial arrangement.

Stop risankizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as:

A 75% reduction in the PASI score (PASI 75) from when treatment started or

A 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from when treatment started.

If patients and their clinicians consider risankizumab to be one of a range of suitable treatments, including guselkumab, secukinumab and ixekizumab, the least expensive should be chosen (taking into account administration costs, dosage, price per dose and commercial arrangements).

When using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate.

When using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DLQI and make any adjustments they consider appropriate.

These recommendations are not intended to affect treatment with risankizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations:

Risankizumab is proposed as an alternative to other biological therapies already recommended by NICE for treating severe plaque psoriasis in adults. Evidence from clinical trials shows that risankizumab is more effective than adalimumab and ustekinumab. Indirect comparisons suggest that risankizumab is likely to provide similar health benefits compared with guselkumab, and better PASI response rates compared with many other biologicals.

For the cost comparison, it is appropriate to compare risankizumab with guselkumab. The total costs associated with risankizumab are similar to or lower than those associated with guselkumab. Therefore, risankizumab is recommended as an option for use in the NHS for severe plaque psoriasis that has not responded to systemic non-biological treatments, or if these are contraindicated or not tolerated.

Some of our members got together and decided the Dermatology Life Quality Index (DLQI)  used by dermatologists didn't give a good representation of how psoriasis affects our daily life, so we decided to make our own version.

Psoriasis can have a huge impact on ones quality of life, and it is important to discuss with your dermatologist/doctor how it affects you. By keeping a score you will be able to see how your quality of life changes each month, this information can be helpful to monitor your treatment and to have some information for your next dermatology/doctor appointment.

Anyone can use it and members can add their score to their profile or keep a note of it in their personal notepad.

You can find it in the top menu next to the NO LINKS ALLOWED or just click here PQOLS

Lilly says that Taltz beats Tremfya in a head to head trial achieving skin clearance at week 12.

Quote:

---

Eli Lilly announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.

At 12 weeks, Taltz met the primary endpoint by demonstrating superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA as measured by PASI 100. In addition, Taltz met all major secondary endpoints up to week 12, which include superiority over TREMFYA in the proportion of patients achieving PASI 75 at Week 2, PASI 90 at Weeks 4 and 8, PASI 100 at Weeks 4 and 8, static Physician's Global Assessment (sPGA) 0 at Week 12 and PASI 50 at Week 1. Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020.

"Completely clear skin and rapid relief of symptoms are possible for many people living with moderate to severe plaque psoriasis, and should be two topics dermatologists discuss with their patients," said Andrew Blauvelt, M.D., M.B.A., dermatologist and president of Oregon Medical Research Center in Portland, OR. "Head-to-head data like these are important and will help inform individual treatment goal discussions between healthcare providers and their patients."

A total of 1,027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of Taltz compared to TREMFYA. Participants were randomized to receive Taltz (160 mg at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks) or TREMFYA (100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter) for a total of 24 weeks, with the primary analysis conducted at 12 weeks.

"Lilly's goal is to raise the treatment bar for people living with psoriasis," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "And research shows that patients want clear skin and rapid improvements. We're pleased to see that Taltz helped more people achieve 100 percent skin clearance compared to TREMFYA at week 12. These positive results reinforce that Taltz is an important treatment option for people with this disease."

In IXORA-R, the safety profile of Taltz was consistent with previously reported results. No new safety signals were detected.

Lilly plans to submit detailed data from the IXORA-R study for disclosure at scientific meetings and in peer-reviewed journals. 

This study suggests patients unlikely to respond to Ilumya / Ilumetri (tildrakizumab) could be identified by week 8, and those likely to achieve a PASI  >90 response could be identified as early as week 4.

Quote:

---

Background:
Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks.

Objectives:
To examine the efficacy of tildrakizumab and its impact on quality of life (QoL) in patients with different levels of week‐28 Psoriasis Area and Severity Index (PASI) improvement.

Methods:
Patients treated with tildrakizumab 100 mg or 200 mg from baseline to week 28 were pooled from reSURFACE 1 and reSURFACE 2 and classified into five mutually exclusive week‐28 PASI improvement groups for each dose: PASI 0‐49, 50‐74, 75‐89, 90‐99, and 100. Mean PASI improvement and Dermatology Life Quality Index (DLQI) 0/1 over time were examined for each group.

Results:
Of 1,156 patients, 575 were in the 100‐mg and 578 in the 200‐mg cohorts, respectively. At week 28, 8.3%, 14.3%, 23.8%, 30.4%, and 23.1% in the 100‐mg and 4.0%, 18.1%, 19.6%, 29.1%, and 29.3% in the 200‐mg cohort achieved PASI <50, 50‐74, 75‐89, 90‐99, and 100, respectively. Patients with PASI <50 at week 28 could be identified as early as week 8, and those with week‐28 PASI ≥90 had approximately 50% PASI improvement by week 4. Among patients achieving PASI >50 at week 28 who continued the same dose of tildrakizumab to week 52, mean PASI improvement was maintained or improved over time. Similar results were observed for both doses. Higher proportions of patients achieved DLQI 0/1 in higher week‐28 PASI groups, and DLQI 0/1 was maintained or improved to week 52. However, not all patients with PASI 100 had DLQI 0/1.

Conclusion:
Patients unlikely to respond to tildrakizumab could be identified by week 8, and those likely to achieve a PASI >90 response could be identified as early as week 4. Week‐28 PASI improvement level correlated with QoL improvement.

Hello, I just joined the group a few minutes ago.  I am so glad to have found this forum so I don't feel so alone now.  I also have Multiple Sclerosis.  With the MS and the psoriasis both being an autoimmune disease it complicates the way in which the psoriasis can be treated. 

I am married and we have three children - all grown and 2 grandchilddren with the youngest graduating from high school this year.  So this coming year they will both be in college.  My husband and I are both retired.  We sold our home a couple of years ago to downsize and are in an apartment at this time.  We have not decided whether to stay in Raleigh, NC or move to another area.  We really like the Ashville area but have lived in Raleigh for about 17 years now so I really don't know if I want to move to another area.  It's harder after you get older to think about adjusting to a new place and having to find new doctors, dentist, church, etc. so we may just stay put. 

My husband is a golfer and fly fisherman so he has really enjoyed being able to do both since retirement.  I love any type of craft.  I crochet, knit,  and sew.   I love to take old vintage linens. especially the white ones, and recycle them into new items.  I also love to watch Turner Classic Movies.  I prefer the old movies to the new ones.  Much less violence and profanity.

That's pretty much my profile at this time and I look forward to being a part of the group.

Nomorepeggy

Hello All,

I have had Psoriasis in one form or another since I was about 5 years old.  Back then, it was on my ankles.  I went away after several years.  Then in my early teens, I got it on my knees for several years before it went away.  Then in my mid twenties I got it on my knuckles and have had it for several years.  I am not 57 and about 4 years ago I started getting it on the side of one of my fingers and now the palm of my right had, unfortunately I am right handed.  I have been dealing with it and hoping it would disappear after a couple of years but it has been getting larger and larger.  Up until a few weeks ago the fold lines of my hand did not have plaques.  But then they started getting it.  Now my entire palm and the skin will crack in those folds.  As some of y'all know, that is pretty painful.  I cannot do much around the yard anymore because of it.  Every time someone wants to shake my hand I really hate it.  I really wish that social norm would just go away.  So the past two weeks I started taing Glutamine and using Coal Tar.

Just joined. For years I've used the clear tape, hadn't had a flare up in years. I have small patches on my shoulder and arm and a different type on my elbows. the patches on my arm are red and raw and very itchy in this heat. I can't remember what they are called. I'm pretty sure antibiotics caused this bad flare up. I stopped taking them a couple weeks ago, just when this flare up started. I am currently trying cbd cream. I am here to read and learn. 

Hi there,
I am new but old here as in the last time I posed ( under a diff name ) was back in 2011. I have very bad guttate and plaque p which can cover up to 75% of my body. I have had this disease since I was 13- I’m 36 now.
I had been keeping my p under control for 8years with Fumaderm. I found it a wonder drug. I had the usual side affects but managed them by taking my full dose which was 8x 120 mg at night before bed. I would have very predicable flushes, cramps and “toilet rushes” in the morning and the rest of the day would be a clear skin pleasure. Exactly this time last year I fell pregnant whilst on Fumaderm _ planned / not planned but very welcomed and naturally had to come off Fumaderm.  My skin flared badly and quickly. I had two lengthy sessions of light treatment to see me through what was otherwise a healthy pregnancy but as soon as I stopped, My skin flared massively again. Having returned to my dermatologist 6weeks post partum  I’m now on skilarence. I turned down Sterala as I was so confident in Fumeric acid \ DMF . I’m now 6 weeks into treatment and I only see mild improvement. I’m also experiencing little or no side affects ... So much so that I actually went and tried some of my old stash of Fumaderm to see if it would work but little reaction to it as well.

I’m on 5x120 this week moving to 6x 120 next week. I expected to see a better result by now and wonder does the lack of side affects indicate that this time it’s not going to work for me   

I’ll keep you updated as I move through this journey.

Thank you for the amazing content - this is an invaluable resource.

Arls x